Mirati Therapeutics worth goal lowered to $84 from $110 at Piper Sandler
Piper Sandler analyst Swapnil Malekar lowered the agency’s worth goal on Mirati Therapeutics to $84 from $110 and retains an Obese ranking on the shares. The corporate’s investor occasion offered extra readability on the response charges in sufferers damaged down by TPS scores the place information appears largely consistent with the present normal of care, thus elevating considerations on the applicability of ada+pembro mixture within the entrance line setting, Malekar tells traders in a analysis observe. Nevertheless, the analyst says that given longer follow-up sufferers confirmed enhanced efficacy and a majority of sufferers proceed to obtain the mixture remedy, he expects to see deepening of responses with longer therapy period.
Printed first on TheFly
See the highest shares beneficial by analysts >>
Learn Extra on MRTX:
